A cancer clinical trial is a carefully controlled research study that tests new treatments, drugs, or approaches in people with cancer. These studies are how every effective cancer therapy, from chemotherapy to immunotherapy, proved it was safe and worth using. Trials follow a structured process with built-in safety protections, and participation is always voluntary.
How Trials Are Structured in Phases
Cancer clinical trials move through distinct phases, each with a different goal. A treatment must clear one phase before advancing to the next, and many don’t make it through.
Phase 1 trials are the first time a treatment is tested in people. The primary goal is safety: finding the right dose, determining the best way to deliver the treatment (by mouth, by IV, etc.), and watching for dangerous side effects. These are small, typically involving 15 to 50 patients. Researchers also look for early signs that the cancer responds, but that’s not the main point yet.
Phase 2 trials test whether the treatment actually works against a specific type of cancer. Fewer than 100 patients typically participate. Side effects are still closely monitored, but the central question shifts to effectiveness.
Phase 3 trials are the big test. They compare the new treatment directly against the current standard treatment to see if it’s better. These trials can involve hundreds to thousands of patients across multiple hospitals or countries. Positive Phase 3 results are usually what leads to regulatory approval.
Phase 4 trials happen after a treatment has already been approved. They track long-term side effects and gather more data on how the treatment performs in larger, more diverse populations over time.
Why Trials Use Randomization
In Phase 3 trials especially, participants are randomly assigned to either the new treatment or the standard treatment. This isn’t arbitrary. If doctors got to choose which patients received which treatment, their choices could skew the results, even unintentionally. A doctor might, for example, assign healthier patients to the new drug, making it look more effective than it really is.
Randomization works like a coin flip: it distributes patients across treatment groups so that both groups end up with similar characteristics overall. This way, any difference in outcomes can be attributed to the treatment itself rather than to differences between the people receiving it. Sophisticated methods keep the groups balanced over time, so one arm doesn’t end up with a cluster of patients enrolled during a particular period, which could introduce its own distortions.
In some trials, neither the patient nor the treating team knows which group a participant is in. This “blinding” prevents expectations from influencing how symptoms are reported or assessed. With newer targeted cancer therapies that have milder side effects than traditional chemotherapy, blinding has become more feasible than it was in the past, when the harsh side effects of treatment made it obvious who was receiving the drug.
Placebos in Cancer Trials
One common fear is being given a sugar pill instead of real treatment. In cancer trials, placebos are never used in place of an effective standard therapy. If a proven treatment exists for your cancer, you will receive it. A placebo might be added on top of standard treatment in some trials, where one group gets standard care plus the new drug and the other gets standard care plus a placebo. This design tests whether the new drug adds benefit beyond what’s already available. Patients with advanced cancers were historically never given placebos at all, and even now, strict ethical review is required before any placebo use is approved.
Newer Trial Designs
Traditional trials test one drug for one cancer type. Newer designs are more flexible. A basket trial tests a single targeted therapy across multiple cancer types that share the same genetic mutation. If a lung cancer and a colon cancer both have the same molecular change driving their growth, the same drug might work for both, and a basket trial can test that simultaneously.
An umbrella trial works in the opposite direction. It focuses on one cancer type but sorts patients into subgroups based on their tumor’s genetic profile, then tests a different targeted therapy in each subgroup. A platform trial goes further still, running multiple treatment comparisons at once against a shared control group. Treatments that aren’t working can be dropped and new ones added without starting an entirely new study. These designs let researchers answer more questions faster.
Who Can Join a Trial
Every trial has eligibility criteria, a list of requirements that determine who can and can’t participate. These aren’t arbitrary gatekeeping. They exist to protect patients and to make sure the results are scientifically meaningful.
Common inclusion criteria involve having a specific cancer type and stage, adequate organ function, and a certain level of physical fitness (often measured by how well you can carry out daily activities). Many trials require that you haven’t had another type of cancer within the past three to five years, with exceptions for low-risk cancers like non-melanoma skin cancer.
Common exclusion criteria include active infections such as HIV or hepatitis B/C, serious psychiatric conditions, substance abuse history, autoimmune diseases, or brain metastases. Prior treatments matter too. Some trials want patients who haven’t yet received any therapy for their cancer, while others specifically seek people whose cancer has progressed through earlier treatments.
Safety Protections for Participants
Multiple layers of oversight protect people in clinical trials. Before a trial can begin enrolling patients, an Institutional Review Board, a committee that includes scientists, doctors, and community members, must review the study’s design and approve it. This board evaluates whether the potential benefits justify the risks and whether the consent process is adequate.
Once a trial is running, an independent group of experts called a Data and Safety Monitoring Board reviews the incoming data at regular intervals. If the new treatment is causing unexpected harm, or if it’s working so well that it would be unethical to keep giving the comparison group the standard treatment, this board can recommend stopping or modifying the trial.
What Informed Consent Covers
Before joining a trial, you go through a formal informed consent process. This isn’t just signing a form. The research team must explain, in language you can understand, exactly what the study involves: its purpose, how long your participation will last, which procedures are experimental, and what the known risks and potential benefits are. You must also be told about alternative treatments available to you outside the trial.
The consent document will describe how your medical records and identity will be protected, who to contact if you have questions or experience a problem, and whether compensation or medical treatment is available if you’re injured as a result of the research. Critically, consent includes a clear statement that your participation is voluntary. You can leave the trial at any time, for any reason, without losing access to your regular medical care or any benefits you’re otherwise entitled to.
Who Pays for What
Costs in a clinical trial fall into two categories. Research costs, the expenses that exist only because the trial exists, are typically covered by the trial’s sponsor. These include the study drug itself, lab tests done purely for research purposes, imaging scans required by the trial protocol, and extra doctor visits beyond what your normal care would require.
Patient care costs are the expenses you’d have regardless of whether you were in a trial: regular doctor visits, hospital stays, standard cancer treatments, and management of side effects. These are usually billed to your health insurance the same way they would be outside a trial. Travel, lodging, meals, and parking are generally your responsibility, though some trials offer financial assistance or can connect you with support organizations that help cover these expenses. It’s worth asking the research team directly.
How to Find a Trial
ClinicalTrials.gov is the most comprehensive public database of clinical studies. You can search by your specific cancer type, the treatment being tested, your location (city, state, zip code, or country), and the trial phase. Every registered trial has a unique NCT number, an eight-digit identifier you can use to pull up its full record, including eligibility criteria, study sites, and contact information.
The site lets you filter by study status (recruiting, not yet recruiting, completed), eligibility criteria, whether results have been posted, and more. Your oncologist can also help identify trials that match your diagnosis and treatment history, and many cancer centers have staff dedicated to matching patients with open studies.